Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT06326086 2024-03-22

Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

Unknown

240 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Sarcopenia

NCT06207292 2024-01-16

STARTNEWERA-OM

Phase NA Unknown

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05418660 2023-09-18

I-STOP

Unknown

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06031597 2023-09-13

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Phase 3 Unknown

105 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT05111197 2023-02-21

TRAILOCLORI01

Phase 3 Unknown

112 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05486988 2022-08-04

ctDNA as a Biomarker for Treatment in Advanced NSCLC

Unknown

500 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05460195 2022-07-15

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Phase 2 Unknown

42 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT04690686 2022-03-08

Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

Phase 2 Unknown

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05137912 2022-02-07

Neoadjuvant Immunotherapy in Advanced NSCLC

Unknown

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04291092 2021-09-10

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Phase 2 Unknown

63 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

STARTNEWERA-OM

I-STOP

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

TRAILOCLORI01

ctDNA as a Biomarker for Treatment in Advanced NSCLC

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

Neoadjuvant Immunotherapy in Advanced NSCLC

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM